In United States v. Novartis Pharmaceuticals Corp. and BioScrip, Inc., provided expert testimony for Novartis on the economics of pharmacy dispensing, government reimbursements, and adherence in connection with alleged FCA violations associated with alleged kickbacks concerning Novartis’s distribution of two specialty brand-name pharmaceuticals: Myfortic and Exjade.
Partner with a firm that delivers rigorous economic research and practical advice.
By using this site, you agree to our updated Cookie Policy, Privacy Policy, and our Terms & Conditions.
When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use cookies, please see our Cookie Policy and Privacy Policy.
